Meeting
2015 ASCO Annual Meeting
Gemcitabine (G), capecitabine (C) and bevacizumab (BV) in patients with advanced biliary cancers (ABC): final results of a multicenter phase II study.
Authors
Renuka V. Iyer
Roswell Park Cancer Institute, Buffalo, NY
Renuka V. Iyer , Adrienne Groman , Wen Wee Ma , Usha Malhotra , Dan Iancu , Catherine Grande , Tanios S. Bekaii-Saab
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01007552
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4078)
DOI
10.1200/jco.2015.33.15_suppl.4078
Abstract #
4078
Poster Bd #
188
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.
First Author: Zhen-gang Yuan
Poster
2023 ASCO Annual Meeting
Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.
First Author: William Joseph Chapin
Poster
2022 ASCO Annual Meeting
Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
First Author: Vaibhav Sahai
Poster
2021 ASCO Annual Meeting
A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04).
First Author: Vaibhav Sahai